Search
UB-612
go.drugbank.com/drugs/DB16444InvestigationalIt was able to reduce viral load and prevent COVID-19 infection in a mouse challenge model and in rhesus macaques[L30653, L30658]. … In rats, toxicity studies have so far shown favourable safety for this vaccine[L30653, L30658], Phase 1 trial is currently ongoing in Taiwan (NCT04545749).
Hycanthone
go.drugbank.com/drugs/DB14061ExperimentalPotentially toxic, but effective antischistosomal agent, it is a metabolite of LUCANTHONE. Hycanthone was approved by the FDA in 1975 but is no longer used.
Chlorcyclizine
go.drugbank.com/drugs/DB08936ApprovedChlorcyclizine is a first generation phenylpiperazine class antihistamine used to treat urticaria, rhinitis, pruritus, and other allergy symptoms. … Chlorcyclizine also has some local anesthetic, anticholinergic, and antiserotonergic properties, and can be used as an antiemetic.
Vorbipiprant
go.drugbank.com/drugs/DB16111InvestigationalCR6086 is under investigation in clinical trial NCT03163966 (A Study of the EP4 Antagonist CR6086 in Combination With Methotrexate, in Dmard-naïve Patients With Early Rheumatoid Arthritis).
siG12D LODER
go.drugbank.com/drugs/DB16329InvestigationalsiG12D LODER is under investigation in clinical trial NCT01676259 (A Phase 2 Study of Sig12d LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer).
Zirconium panitumumab Zr-89
go.drugbank.com/drugs/DB19228InvestigationalZirconium panitumumab Zr-89 is under investigation in clinical trial NCT05423197 (Study Evaluating Zr-panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in Head and Neck Squamous
EGT-301
go.drugbank.com/drugs/DB17649ExperimentalIt consists of an adeno-associated viral vector serotype 9 (AAV9) containing the human Iduronate-2-sulfatase (I2S) transgene designed to restore I2S functional deficiency in patients with Hunter syndrome … EGT-301 is a gene therapy being investigated for Hunter Syndrome.
CX-2009
go.drugbank.com/drugs/DB16090InvestigationalCX-2009 is under investigation in clinical trial NCT03149549 (PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors).
AM103
go.drugbank.com/drugs/DB05225ExperimentalIt is being developed by Amira. … AM103 is a novel inhibitor of 5-lipoxygenase-activiting protein (FLAP) that has demonstrated potential to treat asthma and cardiovascular disease by preventing the synthesis of LT, which triggers inflammation